Floatz Rating
B62/100
Confidence
Indicative
Sponsor
SRH Wald-Klinikum Gera GmbH
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07092410CT.gov Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib | — | Withdrawn | — | — | — |
NCT07022457CT.gov UK ENcorafenib and BInimetinib Real-world Study in Melanoma | — | Active Not Recruiting | — | — | — |
NCT06887088CT.gov Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases | — | Recruiting | — | — | — |
NCT05304546CT.gov Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | — | Completed | — | — | — |
NCT05954546CT.gov A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings | — | Completed | — | — | — |
NCT05810740CT.gov Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | — | Completed | — | — | — |
NCT04903119CT.gov Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | — | Recruiting | — | — | — |
NCT05026983CT.gov Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | — | Recruiting | — | — | — |
NCT05103891CT.gov Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations | — | Unknown | — | — | — |
NCT04759846CT.gov Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | — | Withdrawn | — | — | — |
Show 9 more trialsShow fewer
NCT04511013CT.gov A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | — | Recruiting | — | — | — |
NCT05611229CT.gov Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | — | Completed | — | — | — |
NCT03898908CT.gov Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain | — | Completed | — | — | — |
NCT03235245CT.gov Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | — | Active Not Recruiting | — | — | — |
NCT03864042CT.gov Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | — | Completed | — | — | — |
NCT02910700CT.gov Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02631447CT.gov Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | — | Completed | — | — | — |
NCT02263898CT.gov Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | — | Withdrawn | — | — | — |
NCT01320085CT.gov A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Binimetinib (this asset) | SRH Wald-Klinikum Gera GmbH | Approved | B · 62 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| Montanide Isa 51 | Ludwig Institute for Cancer Research | P2 | BB |
| Therapeutic Autologous Lymphocytes | Fred Hutchinson Cancer Center | P2 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Binimetinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm In The Colon | — | P3 | BB · 70 |
| Cutaneous Melanoma | — | P3 | BB · 68 |
| Triple-Negative Breast Carcinoma | — | P2 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Binimetinib in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/binimetinib-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →